NYMX Nymox Pharmaceutical Corporatio

3.96
+0.13  (3%)
Previous Close 3.83
Open 3.81
Price To book 0.00
Market Cap 199.78M
Shares 50,449,000
Volume 442,858
Short Ratio 7.67
Av. Daily Volume 239,864

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Data released February 2016 met endpoint
NX-1207 long-term NX03-0040 trial
Low grade localized prostate cancer
Phase 3 endpoints met in extension trial July 2015. Noted March 28, 2017 that regulatory filing is due during the next few weeks.
NX-1207 Fexapotide
BPH